MBX 2109, an experimental hormone replacement therapy that MBX Biosciences is developing for hypoparathyroidism, has been granted orphan drug…
Articles by Marisa Wexler, MS
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
A new study out of the Netherlands has found a high incidence — 15% — of long-term hypoparathyroidism in…
AZP-3601, an investigational treatment for chronic hypoparathyroidism, was able to safely increase blood calcium levels in healthy volunteers in a…
Typically, it takes nearly three months before people newly diagnosed with chronic, post-surgical hypoparathyroidism arrive at a stable dose of…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
Ascendis Pharma is requesting regulatory permission to open a Phase 3 clinical trial in Japan, part of its program…
People with hypoparathyroidism in Argentina, particularly those with kidney problems and high levels of phosphate in the blood, frequently…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…